ETF Fundamental Report for VXF
- Vanguard Extended Market ETF (VXF) Overview: VXF is a Mid-Cap Multi-Factor ETF with a significant exposure to the Technology sector, particularly Software & Programming.
- ETF Factor Exposure: The report provides a detailed analysis of VXF's exposure to major investing factors such as value, quality, momentum, and low volatility, with scores ranging from 1 to 99.
- Additional Research Links: The report includes links to top Technology ETFs, High Momentum ETFs, Top Low Volatility ETFs, and High Fundamental Momentum ETFs for further exploration.
- About Validea: Validea is an investment research service that analyzes stock and offers model portfolios based on strategies of investment legends like Warren Buffett, Benjamin Graham, Peter Lynch, and Martin Zweig.
- Disclaimer: The views expressed in the report are those of the author and may not necessarily represent the views of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Analyst Views on VXF
About the author
BFRG Stock Soars Over 100% Today — What’s Behind the Rise?
Stock Surge: Bullfrog AI Holdings Inc. (BFRG) shares rose over 114% in pre-market trading following the announcement of a deal with a major global pharmaceutical company.
Strategic Agreement: The agreement requires Bullfrog AI to utilize its bfLEAP program to identify and prioritize novel drug targets for major depressive disorder (MDD).
Development Goals: The company aims to accelerate its drug discovery and clinical development programs through this partnership.
Market Sentiment: Retail sentiment around Bullfrog AI is currently described as "extremely bullish," with high message volumes noted at the time of reporting.
ROMA Stock Rises 10% Today – Key Details on Its Massive Share Buyback Initiative
Stock Performance: Roma Green Finance shares surged over 10% in pre-market trading following the announcement of a $100 million share repurchase program.
Program Details: The share repurchase program, authorized by the company's board of directors, will remain effective until December 31, 2028.
Market Sentiment: Retail sentiment around Roma Green Finance is currently bullish, with message volumes reported at high levels.
Further Updates: Investors can receive updates on this developing story directly from Stocktwits.
CUE Stock Declines Following CEO's Departure After Only Six Months
Leadership Change: Cue Biopharma's shares dropped 8% after the announcement that CEO Usman Azam stepped down, effective March 26, after only six months in the role. Lucinda Warden has been appointed as the interim president and CEO.
Clinical Trials Progress: The company is focusing on advancing its lead investigational drug, CUE-401, into clinical trials in the second half of the year, targeting autoimmune and inflammatory diseases.
Collaboration Agreement: Cue Biopharma entered a collaboration and license agreement with ImmunoScape to develop a novel in vivo approach for cell therapy aimed at treating solid tumors.
Stock Performance: Cue Biopharma's stock has seen a significant decline of 76% over the past 12 months, with retail sentiment remaining bearish despite some recovery in messaging volume.
KOPN Shares Drop Due to Decrease in Q4 Revenue - What’s Driving Retail Optimism?
Revenue Decline: Kopin Corporation reported a significant year-over-year decrease in revenues, primarily attributed to a government shutdown and associated procurement delays, impacting their fourth-quarter performance.
Financial Performance: The company's total revenues for the fourth quarter ending December 27, 2025, were $8.4 million, down from $14.6 million in the previous year, missing analysts' expectations.
Future Outlook: CEO Michael Murray anticipates continued impacts from the government shutdown into Q1 2026 but remains optimistic about the company's strategic positioning and pipeline strength.
Market Sentiment: Retail sentiment around Kopin has been described as "extremely bullish," with expectations for improved performance in the second quarter, despite a 24% decline in shares so far this year.
ATOS Shares Decline Post-Market Following Earnings Disappointment — CEO Focuses on Innovative Applications for Experimental Cancer Treatment
Company Financial Performance: Atossa Therapeutics reported a net loss per share of $4.04 for 2025, an increase from a loss of $3.04 in 2024, alongside rising operating expenses due to research and development costs.
FDA Designations: The company received Rare Pediatric Disease designation for its investigational therapy for Duchenne Muscular Dystrophy (DMD) in December and Orphan Drug designation in January, which are expected to expedite FDA review processes.
Stock Market Reaction: Following the financial report, Atossa's stock dropped 4% after hours, reflecting ongoing investor concerns, with the stock having fallen 50% over the past year.
Future Focus: Atossa plans to prioritize resources towards oncology and rare disease areas with higher potential returns, while it will not advance its drug for metastatic breast cancer due to cost and timeline constraints.
VNRX Shares Jump 34% in Pre-Market Trading — What’s Fueling the Surge?
VolitionRx Share Price Drop: VolitionRx (VNRX) shares fell over 34% in pre-market trading following the announcement of proof-of-concept data from a blinded validation cohort for cancer detection.
New Liquid Biopsy Method: The company revealed a new liquid biopsy method that achieved over 95% sensitivity for stage I & II cancers, with 95% specificity during the blinded validation cohort.
Retail Sentiment: Retail sentiment around VolitionRx trended bullish, with message volumes reported at extremely high levels at the time of writing.
Updates and Corrections: For ongoing updates and corrections related to this story, readers are encouraged to check Stocktwits.
BFRG Stock Soars Over 100% Today — What’s Behind the Rise?
Stock Surge: Bullfrog AI Holdings Inc. (BFRG) shares rose over 114% in pre-market trading following the announcement of a deal with a major global pharmaceutical company.
Strategic Agreement: The agreement requires Bullfrog AI to utilize its bfLEAP program to identify and prioritize novel drug targets for major depressive disorder (MDD).
Development Goals: The company aims to accelerate its drug discovery and clinical development programs through this partnership.
Market Sentiment: Retail sentiment around Bullfrog AI is currently described as "extremely bullish," with high message volumes noted at the time of reporting.
ROMA Stock Rises 10% Today – Key Details on Its Massive Share Buyback Initiative
Stock Performance: Roma Green Finance shares surged over 10% in pre-market trading following the announcement of a $100 million share repurchase program.
Program Details: The share repurchase program, authorized by the company's board of directors, will remain effective until December 31, 2028.
Market Sentiment: Retail sentiment around Roma Green Finance is currently bullish, with message volumes reported at high levels.
Further Updates: Investors can receive updates on this developing story directly from Stocktwits.
CUE Stock Declines Following CEO's Departure After Only Six Months
Leadership Change: Cue Biopharma's shares dropped 8% after the announcement that CEO Usman Azam stepped down, effective March 26, after only six months in the role. Lucinda Warden has been appointed as the interim president and CEO.
Clinical Trials Progress: The company is focusing on advancing its lead investigational drug, CUE-401, into clinical trials in the second half of the year, targeting autoimmune and inflammatory diseases.
Collaboration Agreement: Cue Biopharma entered a collaboration and license agreement with ImmunoScape to develop a novel in vivo approach for cell therapy aimed at treating solid tumors.
Stock Performance: Cue Biopharma's stock has seen a significant decline of 76% over the past 12 months, with retail sentiment remaining bearish despite some recovery in messaging volume.
KOPN Shares Drop Due to Decrease in Q4 Revenue - What’s Driving Retail Optimism?
Revenue Decline: Kopin Corporation reported a significant year-over-year decrease in revenues, primarily attributed to a government shutdown and associated procurement delays, impacting their fourth-quarter performance.
Financial Performance: The company's total revenues for the fourth quarter ending December 27, 2025, were $8.4 million, down from $14.6 million in the previous year, missing analysts' expectations.
Future Outlook: CEO Michael Murray anticipates continued impacts from the government shutdown into Q1 2026 but remains optimistic about the company's strategic positioning and pipeline strength.
Market Sentiment: Retail sentiment around Kopin has been described as "extremely bullish," with expectations for improved performance in the second quarter, despite a 24% decline in shares so far this year.
ATOS Shares Decline Post-Market Following Earnings Disappointment — CEO Focuses on Innovative Applications for Experimental Cancer Treatment
Company Financial Performance: Atossa Therapeutics reported a net loss per share of $4.04 for 2025, an increase from a loss of $3.04 in 2024, alongside rising operating expenses due to research and development costs.
FDA Designations: The company received Rare Pediatric Disease designation for its investigational therapy for Duchenne Muscular Dystrophy (DMD) in December and Orphan Drug designation in January, which are expected to expedite FDA review processes.
Stock Market Reaction: Following the financial report, Atossa's stock dropped 4% after hours, reflecting ongoing investor concerns, with the stock having fallen 50% over the past year.
Future Focus: Atossa plans to prioritize resources towards oncology and rare disease areas with higher potential returns, while it will not advance its drug for metastatic breast cancer due to cost and timeline constraints.
VNRX Shares Jump 34% in Pre-Market Trading — What’s Fueling the Surge?
VolitionRx Share Price Drop: VolitionRx (VNRX) shares fell over 34% in pre-market trading following the announcement of proof-of-concept data from a blinded validation cohort for cancer detection.
New Liquid Biopsy Method: The company revealed a new liquid biopsy method that achieved over 95% sensitivity for stage I & II cancers, with 95% specificity during the blinded validation cohort.
Retail Sentiment: Retail sentiment around VolitionRx trended bullish, with message volumes reported at extremely high levels at the time of writing.
Updates and Corrections: For ongoing updates and corrections related to this story, readers are encouraged to check Stocktwits.
